רבלימיד 5 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 5 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 10 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 10 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 15 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 15 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 25 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 25 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
רבלימיד 25 מג
neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 25 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.
אוקסליפלטין מדאק 150 מג
tzamal bio-pharma ltd - oxaliplatin - אבקה להכנת תמיסה לאינפוזיה - oxaliplatin 150 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of primary tumor. - treatment on metastatic colateral cancer.
אוקסליפלטין טבע
abic marketing ltd, israel - oxaliplatin - תרכיז להכנת תמיסה לאינפוזיה - oxaliplatin 5 mg/ml - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5- fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of metastatic colorectal cancer.